CG
NYMX

Cutler Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Cutler Group’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,000
Closed -$8K – 6967
2017
Q2 		$8K Buy
25,000
+22,300
+826% +$91.6K ﹤0.01% 4437
2017
Q1 		$1K Sell
2,700
-5,100
-65% -$16.8K ﹤0.01% 6079
2016
Q4 		$4K Buy
+7,800
New +$24.2K ﹤0.01% 5178

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Cutler Group's NYMX Position: Q4 2017 in Review

Cutler Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2017, closing a stake of 103 shares.

Cutler Group first reported a position in NYMX in Q3 2016 and held it in 5 quarters. The position peaked at $50K in Q4 2016. 41 funds tracked by Wall St. Rank hold NYMX as of Q4 2017.

  • Cutler Group reported no remaining Nymox Pharmaceutical Corp position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 103 Nymox Pharmaceutical Corp shares in Q4 2017.
  • Cutler Group first reported a position in Nymox Pharmaceutical Corp in Q3 2016 and held it in 5 quarters.
  • Cutler Group's Nymox Pharmaceutical Corp position peaked at $50K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.